Reading a Stem Cell, Exosome or Amniotic Injection Flyer Line by Line: What the FDA Has Actually Said, What Each Claim Leaves Out and How to Sort Regenerative Medicine in New York City From Marketing

Imagine a flyer slid under an apartment door in Queens, or a banner ad that follows you around after one search for knee pain. It reads something like this: "Regenerate your joints with the power of your own stem cells. Exosome therapy: the next frontier in anti-aging. Amniotic injections rich in growth factors. Walk-in consultations. No surgery. No downtime."

Every phrase on that flyer is a claim, and every claim sits somewhere on a spectrum from well established to unproven to something regulators have warned about. People searching for regenerative medicine in New York, whether they type Manhattan, Brooklyn, the Bronx, Queens or Westchester, are mostly trying to answer a simple question: is any of this real? The honest answer is that parts of it are, parts of it are promising, and parts of it are sold well beyond what anyone has demonstrated.

This guide takes that imaginary flyer apart one line at a time. It explains the vocabulary, what the Food and Drug Administration has said, what the research supports and what it does not, and how a thoughtful person can tell a serious regenerative medicine discussion from a sales pitch. It does not recommend a product, and it does not promise that anything will work. At Liondale Medical, Dr. Bissoon offers regenerative modalities including stem cells, exosomes, PRP and ozone therapy.

"Regenerate your joints": the verb is doing a lot of work

Start with the word regenerate. In medicine it means that lost or damaged tissue grows back as functioning tissue of the same kind. A salamander regenerates a limb. A human liver regenerates after part of it is removed. Cartilage, in an adult human knee, does not reliably regenerate on its own, and no injection has been shown to rebuild a worn joint surface to its original state.

What injections can plausibly do is something more modest: change the chemical environment of a joint, reduce inflammation, provide lubrication or signal cells to behave differently. Those effects, if they happen, can reduce pain. Reduced pain is a real and valuable outcome. It is not the same as new cartilage, and a flyer that uses the word regenerate for a pain-relief effect is borrowing credibility from a stronger claim than the evidence supports.

The field itself is legitimate and growing. Researchers study how cells, signaling molecules and scaffolds might repair tissue, and a few cell-based therapies are approved for specific conditions, mostly in blood disorders and a handful of other diseases. The gap between that research frontier and a walk-in injection is where most of the confusion lives. For readers new to the field, an introductory overview of the basic categories is a useful starting point before judging any single product.

"Your own stem cells": what that phrase can mean

Stem cells are cells that can renew themselves and give rise to more specialized cell types. The flyer implies that a clinic takes your stem cells, concentrates them and puts them where they are needed. There are two things worth separating here.

The first is the source. Autologous means from your own body. Bone marrow concentrate is made by drawing marrow, usually from the back of the pelvis, spinning it to concentrate certain cells and injecting the concentrate. Adipose-derived products are made from fat that has been harvested and processed. These are real procedures performed by physicians, and the cells are your own, which avoids concerns about rejection.

The second is what the concentrate contains and whether it behaves as the marketing suggests. A marrow or fat concentrate is a mixture. It contains platelets, white blood cells and signaling molecules, along with a small number of cells that meet the technical definition of stem or progenitor cells. In many preparations those cells are a tiny fraction of the total, and whether they survive processing, reach the target and do anything useful after injection is debated. Studies of bone marrow concentrate in knee osteoarthritis have reported benefits in some trials and no clear advantage over simpler injections in others, and the quality of the studies varies.

The regulatory side matters too. The FDA has repeatedly stated that, apart from certain blood-forming stem cell products derived from umbilical cord blood for specific blood disorders, it has not approved stem cell products for the orthopedic, neurological, cosmetic or aging uses that clinics often advertise. Cells that are more than minimally manipulated, or used in a way that differs from their original function in the body, are generally regulated as drugs and biologics that require FDA review. Some clinics operate under exceptions, such as procedures done at the point of care for a patient's own tissue, and the details are technical. Anyone considering a cell-based injection should expect the physician to explain, in plain words, which regulatory category the product falls into.

"Exosome therapy: the next frontier": a young category with a regulatory warning attached

Exosomes are tiny membrane-bound packages that cells release. They carry proteins, fats and genetic fragments, and they appear to be one of the ways cells communicate with each other. That biology is real and scientifically exciting, which is exactly why the marketing around exosomes has run ahead of the evidence.

Several things are important to understand. The FDA has publicly warned consumers that no exosome products have been approved for any use, and that products marketed as exosomes are generally regulated as drugs and biologics, which require approval before they are sold. The agency has issued warning letters to companies that marketed exosome products with claims about treating or preventing diseases. In practice that means a vial of exosomes sold for injection or infusion has not gone through the review that would establish what it contains, whether it is safe and whether it works.

Product quality is another worry. Exosome preparations vary enormously depending on the cell source, the method used to isolate them and how they are stored. Standard methods to measure what is actually in a vial are still developing, and the label may say little about the particle count, the purity or the contaminants. A serious clinician will be cautious about claims, will be transparent about the product's regulatory status and will not suggest that exosomes treat conditions such as dementia, arthritis or hair loss.

In plain terms, if a flyer says exosome therapy, ask what is in the vial, who makes it, whether it is an FDA-approved product or sold under an investigational or other pathway, and what evidence in humans supports the use. If the answers are vague, the claim deserves skepticism. Searching for exosome therapy in NYC, Westchester or Nassau County will turn up many offers, and a search result is not an endorsement.

"Amniotic injections rich in growth factors": why this one confuses people

Amniotic products come from donated placental tissue, such as the amniotic membrane or fluid collected after a scheduled cesarean delivery. They are processed, sometimes frozen or dried, and sold to clinics. Marketing often describes them as containing growth factors, hyaluronic acid and sometimes stem cells.

Here the regulatory picture is nuanced. Under FDA rules, certain human tissue products can be sold without a drug-style approval if they are minimally manipulated and intended for homologous use, meaning they perform the same basic function in the recipient as in the donor. A membrane used to cover a wound is closer to that description than a processed fluid injected into a knee to relieve arthritis. The agency has taken the position that many amniotic and similar products promoted for treating disease or injury, outside a narrow set of uses, are regulated as biologics that need approval. It has sent warning letters to firms that marketed such products for conditions ranging from joint pain to eye disease.

There is also a product-content problem. Independent testing of some commercially available amniotic fluid products has found little or no living cells, despite marketing that suggested otherwise, and growth factor levels vary widely. Evidence in humans is limited, with a few small trials and many case series. A flyer that implies amniotic injections contain active stem cells and will repair damaged tissue is going further than the data. For readers who want to follow how a longevity practice weighs unproven interventions in general, the way peptide evidence is graded gives a useful pattern: ask what was tested, in whom and for how long.

"No surgery, no downtime": true as far as it goes

Injection-based treatments generally avoid an operating room, and many people go home the same day. That part of the claim is usually accurate. It leaves out several things.

An injection into a joint or tissue can still cause pain, swelling, infection and bleeding. A bone marrow draw is a procedure with its own discomfort. Rarely, products or technique can cause serious harm, and the FDA and medical journals have documented cases of infections and other complications after unapproved or poorly handled products, including infections traced to contaminated products. Reports have described patients who developed severe joint infections or vision loss after injections given outside proper protocols.

Downtime is also relative. Most physicians advise some relative rest of the treated area and a gradual return to activity, and many protocols include rehabilitation. A plan that promises full activity the same afternoon deserves a second look, since inflammation after an injection can be part of the process.

PRP: the simplest member of the family, and the one with the most data

Platelet-rich plasma sits apart from the products above and deserves its own explanation, because it is often lumped in with them. PRP is made from your own blood. A small amount is drawn, spun in a centrifuge to concentrate platelets and injected into the target area. Platelets carry growth factors and other signaling molecules, and the theory is that concentrating them at an injury site may support healing.

PRP is also the most studied option. Trials and meta-analyses in knee osteoarthritis have generally found that PRP can reduce pain and improve function for some patients over several months compared with placebo or hyaluronic acid injections, though results vary and preparations differ in platelet concentration and white cell content. Evidence is more mixed for tendon problems, and it is limited for hair, skin and other uses. Because PRP involves the patient's own blood processed with devices that have been cleared for preparation, the regulatory questions differ from those surrounding donor-derived products or exosomes.

None of that makes PRP a cure. It is best described as a reasonable, low-risk option with moderate evidence for certain conditions and uneven results, and it deserves the same honest framing as anything else.

The word "rejuvenate" and the longevity version of the flyer

A second version of the flyer targets aging itself: infusions of cells or exosomes to rejuvenate the body, reverse aging or restore youthful energy. This is where claims run furthest ahead of evidence.

There is serious research on cell-based approaches to age-related frailty, and it is worth reading about without exaggeration. A frailty study summarized for general readers shows how such work is conducted: defined patient populations, controlled conditions, specific measurements and cautious conclusions. That kind of research happens in regulated settings and is far removed from a systemic infusion sold in a clinic with claims of reversing the clock.

No cell therapy, exosome product or amniotic infusion has been shown to slow human aging. The fundamentals that do have evidence behind them are still the dull ones: muscle, sleep, metabolic health and good measurement. Practices that build a plan from careful measurement first, and add experimental interventions only if they make sense, are approaching the problem in the right order.

The borough question: why location words appear in so many searches

Many people search for these treatments with a place attached: regenerative therapy in Brooklyn, stem cell injections in Queens, regenerative medicine in the Bronx or in Yonkers. Location is a reasonable thing to want, since treatments involve repeated visits and follow-up. It also invites an assumption that proximity equals quality.

Neighborhood does not tell you who is performing the procedure, what they are using or under what authority. New York has excellent academic orthopedic and sports medicine centers where regenerative procedures, mostly PRP and approved or investigational protocols, are performed by trained specialists, and it also has storefront operations with little oversight. A long commute to the right physician may be better than a short walk to the wrong clinic. A practitioner's training, board certification and willingness to say no matter more than a zip code.

Hair, skin and the cosmetic edges of the category

Many searches for these terms are not about joints at all. People ask about regenerative treatments for thinning hair, for skin quality and for sexual function, and clinics market all three. The evidence differs by use. PRP has been studied for pattern hair loss with mixed but sometimes encouraging results, and it works best as part of a plan, not as a standalone fix. Exosome and stem cell products marketed for hair or skin have even less human data than PRP, and some are sold as cosmetic products with no medical review.

The most useful step before spending on any hair treatment is a proper workup, because thinning is often driven by hormones, iron, thyroid function or nutrition, and an injection will not correct those. A hair loss service that starts with labs before treatment reflects that order of operations. A treatment that ignores the cause will tend to disappoint, whatever is in the syringe.

When the joint is already worn: a realistic frame

People most drawn to regenerative injections are often those with advanced arthritis who hope to avoid a joint replacement. This group deserves candor. When imaging shows bone rubbing on bone, injections of any kind are unlikely to restore the joint, and some patients get only a short period of relief. For them, the useful question is how much time and comfort an injection might buy and whether that is worth the cost and the delay in seeing a surgeon.

For earlier or milder arthritis, the calculation changes. Strength training, weight management, targeted physical therapy and sometimes injections can reduce pain and delay surgery. Strong muscles around a joint also protect it, and loss of muscle with age is a quiet driver of joint trouble, which makes muscle loss a real concern. A regenerative injection layered on top of a neglected body is less likely to help than one added to a sound program.

Tendon injuries, partial tears and chronic tendon pain are another common reason people look into PRP and related treatments. The evidence there is mixed, and rehabilitation usually matters more than the injection. A physician who sends you to physical therapy first is not being dismissive; that is often the more effective path.

What a procedure day involves for each product

Understanding the logistics helps separate a medical procedure from a sales event. A PRP session involves a blood draw, a short spin in a centrifuge and an injection, often with ultrasound guidance, and the visit may last an hour or two. Bone marrow concentrate involves a draw from the pelvis under local anesthesia, processing and an injection, and it is a more involved procedure with more soreness. Adipose procedures involve a small fat harvest, also under local anesthesia. Donor-derived products arrive in a vial and are injected, which is simpler to perform and is exactly why the questions about source and regulatory status matter so much.

Afterward, expect soreness, sometimes for days, and instructions on activity. Anti-inflammatory medicines are sometimes restricted in the period after PRP because of theories that they blunt the effect, though the evidence is not settled, and your physician should tell you what applies. If you take blood thinners or have a bleeding disorder, an infection or a cancer history, say so before any procedure.

Cost and insurance without the numbers

Regenerative treatments are usually paid for out of pocket because insurers regard most of them as experimental. Pricing varies with the product, the procedure and the physician, and it is not set out here. What matters more than any figure is how the cost is presented. A fair practice explains what is included, whether repeat treatments are likely to be needed and what happens if the first treatment does not help. It does not push financing, bundle packages tied to a same-day decision or discourage you from taking time to think.

It is also reasonable to weigh the cost against alternatives with strong records. Physical therapy and exercise cost less and have the best evidence for many joint problems. Choosing an experimental treatment can be a legitimate decision, but it should be made with the comparison in view, ideally after precision diagnostics have shown what is actually driving the problem.

How the claims line up, in one view

It can help to see the categories arranged by how much human evidence exists and how clearly the regulatory position is established. This is a general summary and individual products and indications vary.

PRP comes from your own blood, is marketed for healing, joint pain and hair, and has moderate human evidence for knee osteoarthritis and mixed evidence elsewhere. It is made with preparation devices that have been cleared, though uses vary.

Bone marrow concentrate comes from your own marrow and is marketed as stem cells for joints. Trials are mixed, with some positive and others showing no clear advantage, and the regulatory category depends on processing and use.

Adipose concentrate comes from your own fat and is marketed as stem cells from fat. Evidence is limited and mixed, and the regulatory category again depends on processing and use.

Amniotic products come from donated placental tissue and are marketed for growth factors and stem cells. Human evidence is limited to small trials and case series, and many are regulated as biologics when used to treat disease.

Exosomes come from cultured or donor cells and are marketed for cell signaling and anti-aging. Human evidence is very limited, the FDA states that none are approved, and warning letters have been issued.

Approved cell therapies exist for specific diseases, with established evidence for those approved uses, and they are approved only for narrow indications.

Reading a consultation as well as a flyer

The flyer is only the first contact. A serious consultation looks different. The physician reviews your history, examines the area, looks at imaging and often asks about earlier treatments. They explain the diagnosis before proposing a treatment, and they describe the product, its source and its regulatory status without being pressed. They talk about the realistic range of outcomes, including the possibility of no change, and about alternatives such as physical therapy, weight management, bracing, conventional injections and surgery where appropriate.

A sales conversation is shorter. It starts with the product, moves quickly to a package, uses testimonial language and creates urgency. It treats every kind of pain as a candidate. It rarely mentions risk, regulatory status or other options. Patients who notice that pattern lose nothing by leaving and gaining a second opinion.

The same logic applies to physician-led versus staff-led care. A practice where a physician reviews every plan differs sharply from one where treatment is delivered by a rotating staff, and physician-led care matters even more when the treatment is experimental.

What a measured clinic does in this space

A physician practicing regenerative medicine responsibly tends to do a handful of things consistently. They start with a diagnosis, because injecting the wrong target is a waste. They use the simplest option that fits the evidence first. They state clearly what is established, what is investigational and what is unknown. They document informed consent in writing and explain that some options are not covered by insurance. They avoid blanket promises. They refer to other specialists when the problem calls for surgery or other care. And they follow patients afterward, measuring pain, function and any complications, so that results are judged by data instead of memory.

For a longevity-oriented practice in New York, that framework fits within a broader approach built around labs, risk assessment and a plan rather than a menu of procedures. Dr. Bissoon's concierge model favors that kind of sequence: measure, decide, then treat. Liondale's regenerative options belong in that sequence and not at the start of it.

Safety signals worth taking seriously

Beyond what a product claims, several practical signals protect patients. Be wary of any clinic that treats a wide range of unrelated conditions, from arthritis to dementia to erectile dysfunction, with the same product. Be wary of claims of cures, of testimonials presented as proof and of pressure to sign up the same day. Be wary of financing offers attached to experimental treatments. Be wary of anyone who will not name the manufacturer, the lot number or the regulatory status.

Conversely, signs of care include a physician who personally performs or supervises the procedure, sterile technique in a procedure room, written consent that explains risks and the uncertain evidence, a clear follow-up plan and a willingness to document what was injected. Complications should be reportable and known. Patients should leave knowing what was done and why.

Where this leaves someone reading a flyer

Not every claim on the imaginary flyer is false, and not every one is true. Your own blood can be concentrated into PRP with some evidence for certain joint problems. Marrow and fat concentrates are real procedures with mixed results. Amniotic products and exosomes are regulated in ways that most advertising skips, and the human evidence for them is thin. Nothing on the list has been shown to reverse aging.

A sensible reader keeps the useful part of the flyer, which is curiosity about a field that may one day deliver more, and discards the part that substitutes confidence for data. A conversation with a physician who is willing to explain the difference is worth more than any brochure. For those in New York who want to talk it through in person, the regenerative team can explain what is and is not part of their care, and the first visit can be used to ask exactly that.

After the visit: what good follow-up looks like

Whatever is decided, the part that most separates careful care from marketing is what happens afterward. A physician who offers an injection should plan to see you again, record how pain and function changed using the same measures at the start and the follow-up, and note any unexpected reactions. That record is how a practice learns what works for its own patients, and it is how you can judge whether the treatment was worth repeating.

If a first treatment did little, an honest clinician says so and does not simply suggest a second or third round. A reasonable plan includes a point at which you stop and reconsider, whether that means a different treatment, a referral to a surgeon or an acceptance that some pain will be managed rather than eliminated. A good outcome is one where you understand what was done, what changed and what comes next, even when the answer is less dramatic than the flyer.

Frequently Asked Questions

Are stem cell injections FDA approved?

The FDA has approved only certain blood-forming stem cell products derived from cord blood for specific blood disorders. It has stated that it has not approved stem cell products for most orthopedic, cosmetic or anti-aging uses.

Is exosome therapy legal in New York?

The FDA has said that no exosome products are approved for any use and that products marketed as exosomes are generally regulated as drugs and biologics. Ask any clinic for the product's source and regulatory status.

What are exosomes?

Exosomes are tiny membrane-bound packages released by cells that carry proteins and genetic fragments and appear to help cells communicate. Their biology is real, but human evidence for injected exosome products is very limited.

Do amniotic injections contain stem cells?

Independent testing of some commercial amniotic fluid products has found little or no living cells. Marketing language about stem cells in these products should be checked against the manufacturer's data.

What is the difference between PRP and stem cell therapy?

PRP concentrates platelets from your own blood, while stem cell treatments use concentrates from marrow, fat or other sources. PRP has more human data, particularly for knee osteoarthritis, though results vary.

Can regenerative injections regrow cartilage?

No injection has been shown to reliably rebuild adult human cartilage to its original state. Some injections may reduce pain and improve function by changing the joint environment.

Does regenerative medicine reverse aging?

No treatment has been shown to reverse or slow human aging. Research on cell-based approaches to frailty is ongoing in regulated settings and has not produced a standard anti-aging therapy.

Is a stem cell injection safe?

Risks include pain, swelling, infection and bleeding, and serious infections have been documented with contaminated or poorly handled products. Safety depends on the product, the technique and the setting.

How do I judge a regenerative medicine clinic in NYC?

Look for a physician who gives a diagnosis first, names the product and its regulatory status, explains the limits of the evidence, offers alternatives and avoids same-day pressure.

Does insurance cover regenerative injections?

Coverage is limited, and many such treatments are considered experimental by insurers. Ask the practice what is and is not covered before agreeing to any plan.

Does location matter when choosing a regenerative clinic?

Convenience helps with follow-up, but the physician's training, the product's source and the clinic's transparency matter more than the neighborhood.

Should I try simpler treatments first?

Often yes. Physical therapy, weight management, bracing and conventional injections have established records, and a physician can advise when a regenerative option is reasonable to add.

This page was written and medically reviewed by Lionel Bissoon, D.O., founder of Liondale Medical. Dr. Bissoon is a board-certified osteopathic physician specializing in anti-aging and concierge medicine on the Upper West Side of Manhattan.

This content is for educational purposes only and does not constitute medical advice. Individual results may vary. Consult a qualified physician before beginning any new treatment.

Published November 5th, 2026